https://bit.ly/3tPFW7D.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271752 | PMC |
| http://dx.doi.org/10.1183/23120541.00623-2021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Molecular Bacterial Load Assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif.
J Infect
December 2024
German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Division of Clinical Infectious Diseases, Research Center Borstel, Parkallee 1-40, 23845 Borstel, Germany.
Objectives: Early detection of treatment failure is essential to improve the management of drug-resistant tuberculosis (DR-TB). We evaluated the molecular bacterial load assay (MBLA) in comparison to standard diagnostic tests for monitoring therapy of patients affected by drug-resistant TB.
Methods: The performance of MBLA in tracking treatment response in a prospective cohort of patients with pulmonary MDR/RR- and pre-XDR/XDR-TB was compared with mycobacterial culture, mycobacterial DNA detection using GeneXpert (Xpert) and microscopy detection of sputum acid-fast-bacilli.
Artificial intelligence in tuberculosis: a new ally in disease control.
Breathe (Sheff)
October 2024
Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Computational Biology, Neuherberg, Munich, Germany.
The challenges to effective tuberculosis (TB) disease control are considerable, and the current global targets for reductions in disease burden seem unattainable. The combination of complex pathophysiology and technical limitations results in difficulties in achieving consistent, reliable diagnoses, and long treatment regimens imply serious physiological and socioeconomic consequences for patients. Artificial intelligence (AI) applications in healthcare have significantly improved patient care regarding diagnostics, treatment and basic research.
View Article and Find Full Text PDFAmikacin Liposomal Inhalation Suspension for Non-Tuberculous Lung Infection: A Greek Observational Study.
Medicina (Kaunas)
October 2024
Department of Mycobacterial Diseases, "Sotiria" Hospital, 11527 Athens, Greece.
Intravenous amikacin, recommended for severe or recurrent (MAC) infections and as initial treatment for lung disease, is often limited by serious adverse effects such as renal and auditory toxicities. Inhaled Amikacin Liposome Inhalation Suspension (ALIS) enhances pulmonary drug deposition while minimizing systemic adverse effects, and it has recently been introduced as an add-on therapy for refractory MAC infections or when other standard treatments are inadequate. This study aims to retrospectively describe the outcomes of Greek patients with difficult-to-treat non-tuberculous mycobacterial (NTM) lung disease following the addition of ALIS to guideline-based therapy.
View Article and Find Full Text PDFA Case of Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension.
Intern Med
September 2024
Department of Medical Technology, Okayama University Graduate School of Health Sciences, Japan.
A 55-year-old man presented to our hospital with idiopathic pulmonary fibrosis (IPF). He was registered with the Japan Organ Transplant Network the following year due to disease progression. Treatment with clarithromycin, ethambutol, and rifampicin for complications of Mycobacterium avium pulmonary disease was initiated, but sputum conversion could not be achieved.
View Article and Find Full Text PDFEffectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.
BMC Pulm Med
September 2024
Department of Respiratory Medicine Omori Medical Center, Toho University, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Article Synopsis
- Amikacin liposome inhalation suspension (ALIS) showed effectiveness in increasing sputum culture conversion rates in patients with refractory Mycobacterium avium complex pulmonary disease (MAC-PD) after 6 months of treatment in a phase 3 trial.
- A study involving 12 patients at Toho University revealed that 58.3% achieved culture conversion, with factors like shorter previous treatment duration and fewer cavitary lesions on chest CT linked to better outcomes.
- While improvements in chest CT findings were noted, they did not always match with culture conversion results, indicating that the correlation between imaging and treatment success is complex.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!